Why Elevated Lp(a) Could Be Your Biggest Heart Risk

By VirentaNews Staff — May 16, 2026

One in five people may be walking around with a dangerous, invisible threat lurking in their blood: extremely high levels of lipoprotein(a), or Lp(a), a lesser-known but potent contributor to cardiovascular disease. According to a new study analyzing over 20,000 patient records, those with Lp(a) levels above 180 mg/dL face up to a threefold increase in the risk of stroke, heart attack, and cardiovascular death—risks that persist even when traditional cholesterol markers appear normal. Despite its clinical significance, Lp(a) remains largely undetected because it is not included in standard cholesterol panels and causes no symptoms. This means millions may be unaware of their heightened risk until a life-threatening event occurs, underscoring a critical gap in preventive cardiology.

The Silent Epidemic of Lp(a)

Lp(a) has been on the radar of lipid researchers for decades, but only recently has its population-wide impact come into sharp focus. Unlike LDL or HDL cholesterol, which fluctuate with diet and lifestyle, Lp(a) levels are almost entirely determined by genetics, making them stable from childhood and unresponsive to most conventional interventions. The recent study, published in The Lancet, combined data from multiple international cohorts and found that approximately 20% of individuals have elevated Lp(a) levels, with the highest risk concentrated in those exceeding 180 mg/dL—a threshold now associated with severe cardiovascular consequences. With cardiovascular disease remaining the leading cause of death globally, experts argue that identifying this hidden risk factor could be a game-changer in prevention.

What the Study Reveals About Risk

The research team analyzed data from more than 20,000 adults across Europe and North America, tracking cardiovascular outcomes over a median follow-up period of 11 years. Participants with Lp(a) levels above 180 mg/dL were significantly more likely to experience major adverse cardiac events, including fatal and non-fatal strokes, coronary artery disease, and aortic stenosis. Notably, the risk remained elevated even after adjusting for age, sex, smoking status, blood pressure, and LDL cholesterol levels. The study also found a linear relationship: the higher the Lp(a), the greater the risk. This genetic marker appears to promote atherosclerosis and blood clot formation, accelerating plaque buildup in arteries. Despite its potency, testing for Lp(a) is not routine, and many physicians remain unfamiliar with its clinical implications.

Why Screening Isn’t Standard—Yet

Given the strong genetic component and clinical impact of Lp(a), many cardiologists are calling for widespread screening. But barriers remain. Major guidelines, including those from the U.S. Preventive Services Task Force, do not currently recommend universal testing, citing insufficient evidence that early detection leads to improved outcomes. However, organizations like the European Atherosclerosis Society and the National Lipid Association have advocated for at least one lifetime test for all adults. The test itself is simple—a single blood draw—and costs have decreased significantly in recent years. The real challenge lies in treatment: unlike high LDL, elevated Lp(a) cannot be managed effectively with statins or lifestyle changes. But emerging therapies, including antisense oligonucleotides like pelacarsen, are showing promise in clinical trials by reducing Lp(a) levels by up to 80%, potentially altering long-term risk.

Implications for Patients and Public Health

If adopted, routine Lp(a) screening could transform cardiovascular prevention, especially for individuals with a family history of early heart disease. Those identified with high levels could benefit from more aggressive management of other risk factors, such as tighter control of blood pressure and LDL cholesterol. It could also inform decisions about preventive medications like aspirin or PCSK9 inhibitors. For younger adults, detection could prompt earlier lifestyle interventions and monitoring. From a public health perspective, integrating Lp(a) testing into standard care may help close disparities in heart disease outcomes, particularly among populations with higher genetic prevalence, such as those of African descent, who tend to have naturally higher Lp(a) levels. The cost of inaction, researchers warn, could be measured in thousands of preventable deaths each year.

Expert Perspectives

“We’ve been treating the symptom, not the cause, for too long,” says Dr. Naomi Fisher, a hypertension and lipid specialist at Harvard Medical School. “Lp(a) is one of the most important genetic risk factors we’ve overlooked.” However, not all experts agree on the timing of widespread screening. Dr. Eugene Braunwald, a leading cardiologist at Brigham and Women’s Hospital, cautions that while the data are compelling, “we need outcomes trials proving that lowering Lp(a) actually reduces heart attacks before we mandate population-wide testing.” This divide reflects a broader tension in preventive medicine: how to act on strong observational evidence in the absence of definitive interventional trials.

As new therapies move toward approval, the debate over Lp(a) screening is likely to intensify. The phase 3 Lp(a) HORIZON trial, evaluating pelacarsen’s impact on cardiovascular outcomes, is expected to report results by 2025. If successful, it could pave the way for the first targeted treatment for high Lp(a) and solidify the case for early detection. In the meantime, advocacy groups like the Lp(a) Foundation are urging clinicians to test high-risk patients and increase awareness. The question is no longer whether Lp(a) matters—it clearly does—but how quickly medicine can adapt to address it.

Source: ScienceDaily